Accessibility Menu
ImpediMed logo

ImpediMed(ASX) IPD

Market CapA$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-96%
1 Year-88%
1 Month-17%
A$0.01
+0.00%
+0.00Today
ImpediMed last closing stock price
MetricPriceDate
Last closeAUD 0.012026-09-08
ImpediMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.012026-09-01
1 month-16.67%AUD 0.012026-08-07
3 month-16.67%AUD 0.012026-06-10
Year to date-85.29%AUD 0.032025-12-31
1 year-87.5%AUD 0.042025-09-08
3 year-97.06%AUD 0.172023-09-08
5 year-96%AUD 0.132021-09-09
Since inception-99.34%AUD 0.762007-10-24

ImpediMed Financials at a Glance

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$27.34M

Net Income (TTM)

-A$48.14M

EPS (TTM)

-A$0.01

P/E Ratio

-0.43

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.01

Volume

328,878

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.00 - A$0.06

Estimated Earnings Date

Feb 25, 2027

IPD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImpediMed

ImpediMed Limited is a medical software technology provider specializing in bioimpedance spectroscopy (BIS) instruments and software solutions. The company serves markets in Australia, North America, and internationally, focusing on non-invasive devices for evaluating lymphedema and tracking fluid levels in heart failure patients.

Products and Services
  • SOZO: A non-invasive BIS device for lymphedema evaluation
  • SFB7: A single-channel BIS instrument for body composition analysis
  • ImpediVET: A BIS device designed for veterinary applications
Growth Outlook
  • Recent quarterly revenue increased to AUD 7.52 million, showing strong demand
  • Expansion into international markets is expected to drive future growth
  • Innovative product development aims to enhance market position
Financial Highlights
  • Trailing twelve-month revenue of AUD 25.5 million reflects a growing customer base
  • Cash and cash equivalents stood at AUD 18.85 million, providing operational stability
  • Current ratio of 3.74 indicates strong liquidity and financial health
ImpediMed Limited is positioned in the healthcare sector, focusing on innovative medical devices that address critical health issues. The company's flagship products, SOZO and SFB7, cater to both human and veterinary markets, showcasing versatility in application. Recent financial performance indicates a positive trend, with increasing revenues and a solid cash position, which may attract potential investors looking for growth opportunities in the medical device industry. The company's commitment to expanding its product offerings and entering new markets further enhances its growth potential, making it a noteworthy consideration for those interested in the healthcare technology sector.
AI Generated • Aug 21, 2026

Industry

Healthcare Equipment and Supplies

Employees

66

CEO

Erik S. Anderson, CFA

Headquarters

Carlsbad, CA 92008, US

IPD Financials

Key Financial Metrics (TTM)

Gross Margin

-81.36%

Operating Margin

-117.21%

Net Income Margin

-170.44%

Return on Equity

-259.31%

Return on Capital

-82.53%

Return on Assets

-71.86%

Earnings Yield

-2.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.66B

Volume

328.88K

Avg. Volume

6.32M

Financials (TTM)

Gross Profit

-A$914.00K

Operating Income

-A$41.36M

EBITDA

-A$32.57M

Operating Cash Flow

-A$35.25M

Capital Expenditure

A$19.97M

Free Cash Flow

-A$15.28M

Cash & ST Invst.

A$15.29M

Total Debt

A$509.00K

ImpediMed Performance Analysis

ImpediMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 11,344,0007.4%
20242024-06-30AUD 10,319,000-9.0%
20252025-06-30AUD 12,724,00023.3%
20262026-06-30AUD 14,613,00014.8%
ImpediMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-318.5%
Q42025-06-3011.8%
Q22025-12-3111.9%
Q42026-06-30-5.6%
ImpediMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-3.4%
20242024-06-30AUD -0.01-14.0%
20252025-06-30AUD -0.0117.3%
20262026-06-30AUD -0.011.7%
ImpediMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-12.2%
Q42025-06-30-9.1%
Q22025-12-31N/A
Q42026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$7.10M

+28.2%

Gross Profit

-A$5.37M

-210.7%

Gross Margin

-75.71%

N/A

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$277.46K

N/A

Employees

66

N/A

Net Income

-A$12.63M

-25.3%

EBITDA

-A$7.51M

+19.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$15.29M

-37.9%

Total Debt

A$509.00K

-55.5%

Accounts Receivable

A$4.68M

+76.7%

Inventory

A$2.21M

+191.3%

Long Term Debt

A$16.30M

+1912.3%

Short Term Debt

A$296.00K

-11.1%

Return on Assets

-71.86%

N/A

Return on Invested Capital

-60.13%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$10.53M

+4.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GSS.AXGenetic Signatures Limited
A$0.09+7.41%
MX1.AXMicro-X Limited
A$0.02-4.76%
PCK.AXPainChek Limited
A$0.12+4.55%
EYE.AXNova Eye Medical Limited
A$0.14+3.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.03+0.03%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$117.28+0.10%
INTCIntel
$95.80+0.05%

Questions About IPD

What is the current price of ImpediMed?

ImpediMed is trading at A$0.01 per share.

What is the 52-week range for ImpediMed?

Over the past 52 weeks, ImpediMed has traded between A$0.00 and A$0.06.

How much debt does ImpediMed have?

As of the most recent reporting period, ImpediMed reported total debt of A$16.60M.

How much cash does ImpediMed have on hand?

ImpediMed reported A$15.29M in cash and cash equivalents in its most recent financial results.

What is ImpediMed’s dividend yield?

ImpediMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.